IP Library Granted Patent US 7,951,359
Granted Patent B2
US 7,951,359 · App. 11/587,937 · Granted May 31, 2011

Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,359
App. No.
11/587,937
Granted
May 31, 2011
Kind
B2
Abstract

The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN.

Claims (10)

1. A method for treating and/or reducing chemotherapy-induced peripheral neuropathy, comprising administering an effective dose of IL-6 in a range of 0.06 to 3 μg/kg body weight, or a fused protein comprising IL-6 and an immunoglobulin or IL-6 and a constant region of a immunoglobulin, or a salt thereof, to a patient undergoing treatment with at least one chemotherapeutic agent or to a patient in which at least one chemotherapeutic agent is being co-administered, so as to treat and/or reduce chemotherapy-induced peripheral neuropathy.

2. The method according to claim 1 , wherein the patient is a high-risk patient who suffers from chemotherapy-induced peripheral neuropathy.

3. The method according to claim 1 , wherein the patient exhibits high levels of IL-6 receptor in the circulation.

4. The method according to claim 1 , wherein the IL-6, or a fused protein comprising IL-6 and an immunoglobulin or IL-6 and a constant region of a immunoglobulin, or a salt thereof, is administered daily.

5. The method according to claim 1 , wherein the IL-6, or a fused protein comprising IL-6 and an immunoglobulin or IL-6 and a constant region of a immunoglobulin, or a salt thereof, is administered three times per week.

6. The method according to claim 1 , wherein the IL-6, or a fused protein comprising IL-6 and an immunoglobulin or IL-6 and a constant region of a immunoglobulin, or a salt thereof, is administered daily or three times per week for at least two weeks.

7. The method according to claim 1 , wherein the IL-6, or a fused protein comprising IL-6 and an immunoglobulin or IL-6 and a constant region of a immunoglobulin, or a salt thereof, is administered subcutaneously.

8. The method of claim 1 , wherein said at least one chemotherapeutic agent is vincristine.

9. The method of claim 1 , wherein said at least one chemotherapeutic agent is cisplatin.

10. The method of claim 1 , wherein said at least one chemotherapeutic agent is taxol.

Assignments (1)
CHANGE OF NAME Recorded Nov 25, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023569/0120 →